Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
71.50    1.50 (2.14%)
Bid:
71.00
Ask:
72.00
Spread: 1.00 (1.408%)
Market Cap: £325.40m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Final Results

12 Dec 2008 12:06

RNS Number : 0481K
Avacta Group PLC
12 December 2008
 



Avacta Group plc

Audited Results for the year to 31 July 2008

On 4 November 2008, Avacta Group plc ("Avacta", the "Group" or the "Company") announced its preliminary results for the year to 31 July 2008. The preliminary results included intangible assets of £7,144,000 and an other reserve of £1,834,000 reflecting the application of reverse acquisition accounting of the transaction whereby Avacta Limited reversed into Avacta Group plc (formerly Readybuy plc) during August 2006. Upon conversion from accounting under United Kingdom Generally Accepted Accounting Practice to International Financial Reporting Standards as adopted by the European Union, it is possible to recognise a different treatment of this transaction within the financial statements, which the Directors believe to be beneficial.

There is no impact on the income statement or the cash flows of the Group in either the current or comparative accounting period

Accordingly, the consolidated balance sheet of the Group has been adjusted from that included within the Preliminary Announcement to reflect this revised treatment resulting in goodwill of £3,563,000 that had been previously recognised within the intangible assets of £7,144,000 now being recognised within the other reserveThe adjusted consolidated balance sheet is included within this announcement. 

There are no other changes to the Preliminary Announcement.

The Company's full Annual Report & Accounts are available on its website at www.avacta.com

Enquiries:

Avacta Group plc

087 0835 4367

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

Daniel Stewart & Company plc

020 7776 6550

Lindsay Mair / Charlotte Stranner

Novum Securities Limited

020 7562 4700

Henry Turcan

Haggie Financial LLP

020 7417 8989

Nicholas Nelson / Kathy Boate

   

   Consolidated Balance Sheet as at 31 July 2008

2008

2007

£000

£000

Non-current assets

Property, plant & equipment

290

148

Intangible assets

3,581

-

-------------

------------

3,871

148

-------------

------------

Current assets

Trade and other receivables

92

170

Income taxes

84

-

Cash and cash equivalents

1,097

2,527

-------------

------------

1,273

2,697

-------------

------------

Total assets

5,144

2,845

-------------

------------

Current liabilities

Trade and other payables

(234)

(164)

Finance lease obligations

(11)

(11)

-------------

------------

(245)

(175)

-------------

------------

Non-current liabilities

Finance lease obligations

(30)

(41)

-------------

------------

(30)

(41)

-------------

------------

Total liabilities

(275)

(216)

-------------

------------

Net assets

4,869

2,629

-------------

------------

Equity attributable to equity holders of the Company

Called up share capital

900

856

Share premium account

6,524

4,882

Other reserve

(1,729)

(1,729)

Capital reserve

1,899

-

Retained earnings

(2,725)

(1,380)

-------------

------------

Total equity

4,869

2,629

-------------

------------

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR EAAAAFEDPFFE
Date   Source Headline
23rd Feb 20237:00 amRNSAvacta Therapeutics Division Science Day
13th Feb 20237:00 amRNSIssue of Equity and Total Voting Rights
23rd Jan 202312:20 pmRNSIssue of Equity and Total Voting Rights
17th Jan 20232:05 pmRNSSecond Price Monitoring Extn
17th Jan 20232:00 pmRNSPrice Monitoring Extension
17th Jan 202311:05 amRNSSecond Price Monitoring Extn
17th Jan 202311:00 amRNSPrice Monitoring Extension
17th Jan 20239:05 amRNSSecond Price Monitoring Extn
17th Jan 20239:00 amRNSPrice Monitoring Extension
17th Jan 20237:00 amRNSSuccessful Completion of Fourth Dose Escalation
16th Jan 202310:15 amRNSBlock Listing Application to AIM
19th Dec 20227:00 amRNSAvacta to Host Therapeutics Division Science Day
8th Nov 20227:01 amRNSDirector/PDMR Shareholding
8th Nov 20227:00 amRNSResult of the Open Offer
31st Oct 20221:32 pmRNSAvacta to Present at Theranostics FAP Summit
31st Oct 202211:05 amRNSSecond Price Monitoring Extn
31st Oct 202211:00 amRNSPrice Monitoring Extension
28th Oct 20227:00 amRNSBlock Listing Six Monthly Return
20th Oct 20228:01 amRNSDirector/PDMR Shareholding
20th Oct 20228:01 amRNSAdmission of the Company’s Ordinary Shares
20th Oct 20227:00 amRNSPosting of the Company’s Open Offer Circular
18th Oct 202211:49 amRNSResult of Placing
18th Oct 20229:16 amRNSPrivate CB and ABB Launch
18th Oct 20229:14 amRNSProposed acquisition of Launch Diagnostics
29th Sep 20227:00 amRNSInterim Results for the Period Ended 30 June 2022
26th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSAVA6000 receives Orphan Drug Designation from FDA
1st Sep 20227:00 amRNSPhase I study of AVA6000 advances to fourth cohort
21st Jul 20227:00 amRNSAffyXell successfully completes funding round
30th Jun 20227:00 amRNSLG Chem renews license triggers payment to Avacta
29th Jun 20229:05 amRNSSecond Price Monitoring Extn
29th Jun 20229:00 amRNSPrice Monitoring Extension
29th Jun 20227:00 amRNSSecond dose escalation in phase 1 trial of AVA6000
23rd Jun 20224:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20224:36 pmRNSPrice Monitoring Extension
23rd Jun 20224:27 pmRNSResult of Annual General Meeting
16th Jun 20224:41 pmRNSSecond Price Monitoring Extn
16th Jun 20224:36 pmRNSPrice Monitoring Extension
31st May 20227:00 amRNSPosting of Annual Report and Notice of AGM
16th May 202212:00 pmRNSAffyXell expands partnership with GenScript ProBio
11th May 20227:00 amRNSLondon Therapeutics headquarters established
6th May 20227:00 amRNSBlock Listing Application to AIM (update)
28th Apr 20221:53 pmRNSBlock Listing Application to AIM
14th Apr 20225:01 pmRNSIssue of Equity and Total Voting Rights
14th Apr 202211:29 amRNSIssue of Equity and Total Voting Rights
13th Apr 20227:00 amRNSAffyXell milestone and increased equity stake
12th Apr 20227:00 amRNSPoster presented at the AACR available to download
11th Apr 20224:41 pmRNSSecond Price Monitoring Extn
11th Apr 20224:35 pmRNSPrice Monitoring Extension
11th Apr 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.